Perseus Proteomics, Inc. (JP:4882)
:4882
Want to see JP:4882 full AI Analyst Report?
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥203.00 - ¥478.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥4.10B
Enterprise Value¥2.19B
Total Cash (Recent Filing)¥1.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.93
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.42
Shares Outstanding16,999,600
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.33
Price to Sales (P/S)87.24
P/FCF Ratio-13.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~86–94% gross margins indicate strong unit economics and pricing power for the company's core products. Such margins provide a durable cushion as revenue scales, enabling operating leverage to flow to the bottom line if fixed costs are controlled and sales growth continues.
Debt-free Balance SheetA debt-free capital structure materially reduces refinancing and interest-rate risk, giving management flexibility to fund R&D or operations via equity or cash reserves. This structural strength lengthens the runway and lowers default risk during prolonged cash burn.
Sustained Revenue GrowthMulti-year revenue growth, including positive 2025 growth, shows commercial traction and expanding market adoption. When paired with very high gross margins, this trend suggests the business model can scale profitably over time if operating expenses are reined in and sales momentum continues.
Bears Say
Deep And Persistent LossesExtremely negative net margins and recurring operating losses are a structural headwind: they erode shareholder equity, require ongoing external financing, and constrain ability to invest in commercial scale or R&D. This makes achieving sustainable profitability a central long-term risk.
Consistent Negative Cash FlowPersistent negative operating and free cash flow indicates the company's losses translate into real cash burn, reducing financial flexibility. Ongoing cash outflows increase reliance on external capital, raise dilution risk, and limit capacity for organic investment or strategic initiatives.
Eroding Equity / Capital NeedsDeclining equity across multiple years signals capital erosion from losses and heightens the probability of future equity raises. Reduced equity buffers weaken the balance sheet, limit credit capacity, and increase long-term funding and dilution pressure for shareholders.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥203.00 and its highest was ¥478.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥4.10B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is May 14, 2026 which is in 22 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on Feb 13, 2026. The company reported -¥11.42 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.42.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 16,999,600 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.966%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―
Options Prices
Currently, No data available
---